Pregabalin

Generic Name
Pregabalin
Brand Names
Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
Drug Type
Small Molecule
Chemical Formula
C8H17NO2
CAS Number
148553-50-8
Unique Ingredient Identifier
55JG375S6M
Background

Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by bind...

Indication

Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.

Associated Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
Associated Therapies
-
Clinical Trials
Related News

Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

Phase 4
Completed
Conditions
Diabetic Peripheral Neuropathy
First Posted Date
2005-09-12
Last Posted Date
2021-01-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
160
Registration Number
NCT00159731
Locations
🇺🇸

Pfizer Investigational Site, Salt Lake City, Utah, United States

A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)

Phase 4
Completed
Conditions
Diabetic Neuropathy, Painful
First Posted Date
2005-09-12
Last Posted Date
2021-01-25
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
450
Registration Number
NCT00156078
Locations

Pfizer Investigational Site

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

Phase 4
Completed
Conditions
Diabetic Neuropathy, Painful
First Posted Date
2005-09-12
Last Posted Date
2021-01-25
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
167
Registration Number
NCT00159679
Locations
🇺🇸

Pfizer Investigational Site, San Antonio, Texas, United States

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

Phase 4
Completed
Conditions
Post-Herpetic Neuralgia
First Posted Date
2005-09-12
Last Posted Date
2021-01-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
255
Registration Number
NCT00159666
Locations
🇬🇧

Pfizer Investigational Site, Portsmouth, United Kingdom

Safety and Efficacy Study of Pregabalin in Fibromyalgia

Phase 3
Completed
Conditions
Fibromyalgia
First Posted Date
2005-09-09
Last Posted Date
2021-01-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
1020
Registration Number
NCT00151489
Locations
🇺🇸

Pfizer Investigational Site, Charleston, West Virginia, United States

Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder

Phase 3
Completed
Conditions
Anxiety
First Posted Date
2005-09-09
Last Posted Date
2021-01-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
390
Registration Number
NCT00151450
Locations
🇸🇪

Pfizer Investigational Site, Trollhattan, Sweden

An Open-Label Trial of Pregabalin in Patients With Fibromyalgia

Phase 3
Completed
Conditions
Fibromyalgia
First Posted Date
2005-09-09
Last Posted Date
2021-01-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
428
Registration Number
NCT00151528
Locations
🇺🇸

Pfizer Investigational Site, Yakima, Washington, United States

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.

Phase 3
Completed
Conditions
Neuralgia
First Posted Date
2005-09-08
Last Posted Date
2006-12-22
Lead Sponsor
Pfizer
Target Recruit Count
276
Registration Number
NCT00150436

To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.

Phase 3
Completed
Conditions
Diabetic Neuropathy, Painful
First Posted Date
2005-09-08
Last Posted Date
2007-01-01
Lead Sponsor
Pfizer
Target Recruit Count
384
Registration Number
NCT00150423

Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

Phase 3
Completed
Conditions
Anxiety Neuroses
First Posted Date
2005-09-08
Last Posted Date
2006-07-14
Lead Sponsor
Pfizer
Target Recruit Count
511
Registration Number
NCT00150449
Locations

Pfizer Investigational Site

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy